LRI Investments LLC Sells 425 Shares of Dolby Laboratories $DLB

LRI Investments LLC lessened its holdings in Dolby Laboratories (NYSE:DLB) by 35.6% in the second quarter, Holdings Channel reports. The institutional investor owned 769 shares of the electronics maker’s stock after selling 425 shares during the period. LRI Investments LLC’s holdings in Dolby Laboratories were worth $57,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. CWM LLC raised its holdings in Dolby Laboratories by 57.8% in the 2nd quarter. CWM LLC now owns 21,752 shares of the electronics maker’s stock valued at $1,615,000 after buying an additional 7,967 shares during the last quarter. IFP Advisors Inc increased its position in Dolby Laboratories by 10.9% during the 2nd quarter. IFP Advisors Inc now owns 2,675 shares of the electronics maker’s stock valued at $201,000 after purchasing an additional 262 shares during the period. Callan Family Office LLC acquired a new stake in Dolby Laboratories during the 2nd quarter valued at approximately $232,000. KLP Kapitalforvaltning AS increased its position in Dolby Laboratories by 15.0% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the electronics maker’s stock valued at $1,708,000 after purchasing an additional 3,000 shares during the period. Finally, Ameritas Advisory Services LLC acquired a new stake in Dolby Laboratories during the 2nd quarter valued at approximately $48,000. Institutional investors own 58.56% of the company’s stock.

Dolby Laboratories Trading Up 1.0%

NYSE DLB opened at $68.80 on Tuesday. The company has a fifty day simple moving average of $72.14 and a 200 day simple moving average of $73.94. Dolby Laboratories has a 12-month low of $67.83 and a 12-month high of $89.66. The company has a market cap of $6.59 billion, a P/E ratio of 25.20 and a beta of 0.92.

Dolby Laboratories (NYSE:DLB) last posted its quarterly earnings results on Thursday, July 31st. The electronics maker reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.06. Dolby Laboratories had a net margin of 19.62% and a return on equity of 11.52%. The business had revenue of $315.55 million during the quarter, compared to the consensus estimate of $305.23 million. During the same quarter last year, the firm posted $0.71 EPS. Dolby Laboratories’s revenue was up 9.2% compared to the same quarter last year. Dolby Laboratories has set its FY 2025 guidance at 3.880-4.030 EPS. Q4 2025 guidance at 0.610-0.760 EPS. Sell-side analysts predict that Dolby Laboratories will post 2.94 EPS for the current year.

Dolby Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were given a $0.33 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. This represents a $1.32 annualized dividend and a yield of 1.9%. Dolby Laboratories’s dividend payout ratio (DPR) is presently 48.35%.

Insider Buying and Selling at Dolby Laboratories

In other Dolby Laboratories news, SVP Shriram Revankar sold 7,000 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $74.92, for a total transaction of $524,440.00. Following the transaction, the senior vice president directly owned 70,435 shares in the company, valued at approximately $5,276,990.20. This trade represents a 9.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin J. Yeaman sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $71.66, for a total value of $1,791,500.00. Following the transaction, the chief executive officer owned 114,725 shares in the company, valued at approximately $8,221,193.50. This trade represents a 17.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 59,491 shares of company stock valued at $4,310,515. 38.39% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

DLB has been the subject of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Dolby Laboratories in a research report on Friday, September 5th. They set a “neutral” rating and a $74.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Dolby Laboratories in a research report on Wednesday, October 8th. Tigress Financial increased their target price on shares of Dolby Laboratories from $112.00 to $114.00 and gave the company a “buy” rating in a research report on Friday, August 15th. Barrington Research reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Dolby Laboratories in a research report on Friday, September 12th. Finally, Wall Street Zen raised shares of Dolby Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, August 30th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Dolby Laboratories has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.